People with relapsing-remitting multiple sclerosis (RRMS) who switch to Ocrevus (ocrelizumab) after discontinuing Gilenya (fingolimod) have fewer relapses than those who switch to Mavenclad (cladribine) or Tysabri (natalizumab), according to a new study.
Rates of disability worsening were similar for Ocrevus and Tysabri, but patients who switched to Tysabri were more likely to report disability improvements, or less disability, after switching than those on Ocrevus.
https://multiplesclerosisnewstoday.c...ewer-relapses/
Rates of disability worsening were similar for Ocrevus and Tysabri, but patients who switched to Tysabri were more likely to report disability improvements, or less disability, after switching than those on Ocrevus.
https://multiplesclerosisnewstoday.c...ewer-relapses/